Xencor | XNCR - Selling And Administration Expenses


Xencor reported $71.93M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.84B 205M Sep/2026
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
Amgen USD 1.68B 40M Sep/2026
Arrowhead Research USD 46.63M 4.88M Jun/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
Biogen USD 752M 42.3M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Cytokinetics USD 113.14M 8.75M Sep/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
J&J USD 6.25B 168M Sep/2026
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
MacroGenics USD 7.9M 1.81M Jun/2026
Merck USD 2.86B 25M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Xencor USD 71.93M 5.61M Sep/2026